Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 9,400 shares, a drop of 38.6% from the August 31st total of 15,300 shares. Based on an average trading volume of 2,360,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.7% of the company’s stock are sold short.

Salarius Pharmaceuticals Stock Performance

Shares of Salarius Pharmaceuticals stock remained flat at $1.44 during trading on Friday. 30,098 shares of the stock were exchanged, compared to its average volume of 829,901. The firm has a market capitalization of $856,695.00, a P/E ratio of -0.07 and a beta of 0.95. Salarius Pharmaceuticals has a 1-year low of $1.35 and a 1-year high of $7.60. The firm’s fifty day simple moving average is $1.94 and its two-hundred day simple moving average is $3.00.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its quarterly earnings results on Friday, August 9th. The company reported ($2.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($53.60) by $51.23. On average, equities analysts forecast that Salarius Pharmaceuticals will post -214.4 EPS for the current fiscal year.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.